Plasmapp (405000), a bio plasma deep tech company, has signed a supply contract worth approximately 200 billion won with TDF MEDICAL in Australia, focusing on the Australian and New Zealand markets. Plasmapp's low-temperature plasma sterilization device (brand: STERLINK) is not only the first non-US company to receive FDA certification but has also obtained medical device certifications from 45 countries including Canada (HC), Australia (TGA), Brazil (ANVISA), Japan (MHOW), Russia (RZN), and Saudi Arabia (SFDA). As the only small plasma sterilizer with FDA approval in the global medical device market, Plasmapp is rapidly expanding regionally. This contract marks an expansion into the Australian and New Zealand regions, establishing a foothold for business development in the Oceania market. With recent large-scale supply contracts, Plasmapp's cumulative contract amount has reached approximately 3.3 trillion won, with 16 contracts in Korea (approximately 90 billion won) and 35 contracts overseas (approximately 240 billion won), demonstrating significant growth in overseas markets through differentiated and reliable products. Plasmapp is preparing to launch new products while expanding the regional presence and application areas of its low-temperature plasma sterilization device (brand: STERLINK) and implant plasma surface treatment product (brand: ACTILINK), both of which have acquired numerous international medical device certifications. Youbong Lim, CEO of Plasmapp, stated, "Following our recent listing on the KOSDAQ and aiming for rapid growth in the global market, all of our employees are putting forth their best efforts. We will continue to pioneer new markets to grow into a global unicorn company."